Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia

NCT03001557 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Irregular Sleep-Wake Rhythm Disorder

Interventions

DRUG: Lemborexant 2.5 mg
DRUG: Lemborexant 5 mg
DRUG: Lemborexant 10 mg
DRUG: Lemborexant 15 mg
DRUG: Lemborexant-matched placebo

Sponsor

Eisai Inc.

Collaborators

[object Object]